Biotinylated Human ACE2 / ACEH Protein, His,Avitag™ (MALS verified)
分子别名(Synonym)
ACE-2,ACEH,ACE2
表达区间及表达系统(Source)
Biotinylated Human ACE2, His,Avitag (AC2-H82E6) is expressed from human 293 cells (HEK293). It contains AA Gln 18 - Ser 740 (Accession # Q9BYF1-1).
Predicted N-terminus: Gln 18
蛋白结构(Molecular Characterization)
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 87.2 kDa. The protein migrates as 95-125 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
标记(Labeling)
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白标记度(Protein Ratio)
Passed as determined by the HABA assay / binding ELISA.
内毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
纯度(Purity)
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制剂(Formulation)
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH8.0 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
血管紧张素转换酶2(ACE2)也称为ACEH(ACE同源物),是一种与ACE具有相当同源性的完整膜蛋白,属于肽酶M2家族。ACE2是一种外肽酶,催化血管紧张素I转化为九肽血管紧张素,或血管紧张素II转化为血管紧张素1-7。ACE2可能是心脏功能的重要调节因子。在人类冠状病毒SARS和HCoV-NL63感染的情况下,ACE-2作为两种冠状病毒刺突糖蛋白的功能受体。ACE2被氯化物和氟化物激活,但不被溴化物激活,被MLN-4760、cFP_Leu和EDTA抑制,但不受ACE抑制剂利诺昔普利、卡托普利和依那普利的抑制。ACE2在pH 6至9范围内具有活性,在1M NaCl的存在下,最适pH为6.5。
关键字: ACE2;ACE2蛋白;ACE2重组蛋白;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group(股票代码:301080)是成立于2010年的跨国生物科技公司,是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球,横跨亚洲、北美洲、欧洲,在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家,与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。